A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Mount Sinai Hospital-The Donald H. Ruttenberg Cancer Treatment Center, New York

Weill Cornell Medical Center, Div. of Hematology Medical Oncology, New York

Medical College of Wisconsin, Milwaukee

Washington University School of Medicine, St Louis

The University of Texas MD Anderson Cancer Center, Houston

City of Hope - Duarte, Duarte

Oregon Health & Science University Knight Cancer Institute, Portland